Catalyst News and Research

RSS

Experts propose policy solutions to help the U.S. prepare for increasing number of geriatric patients

Leading physician policy experts are calling for changes in medical education policy at multiple levels to ensure that doctors are prepared to treat the country's aging adult population.

6 May 2010

TearScience completes $44.5 million Series C funding

TearScience, a privately-held medical device company, today announced the completion of $44.5 million of Series C funding from new investors Essex Woodlands Health Ventures, Investor Growth Capital and General Catalyst. The company's existing investors, De Novo Ventures, Spray Ventures and Quaker Bio Ventures completed the round. The funding will allow TearScience to commercialize its devices designed for use by eye care professionals to diagnose and treat the most common form of chronic dry eye disease.

5 May 2010

Decisive impact of informatics on nanomedicine

According to what researchers from Facultad de Informática and other institutions have advanced in an article just published in the prestigious medical journal Pediatric Research (Vol.6, No. 5, 2010), nanoparticles are poised to play a key role in medical research in the coming decades, when nanomedicine will become part of medical practice.

5 May 2010

Each year up to 85% of health center patients experience unmet legal needs: Study

Each year, between 50 and 85 percent of health center patients - or between ten and seventeen million people - experience unmet legal needs, many of which negatively impact their health, according to a new study from the Geiger Gibson/RCHN Community Health Foundation Research Collaborative at The George Washington University School of Public Health and Health Services.

5 May 2010

Catalyst Health Solutions' first-quarter 2010 net income up 26%

Catalyst Health Solutions, Inc. announces its financial results for the first quarter ended March 31, 2010. The Company reports quarterly net income of $17.4 million, up 26% from $13.8 million in the prior year. Quarterly earnings per diluted share increased to $0.39. Revenue for the quarter ended March 31, 2010, increased 18% to $832.3 million from $703.3 million in the prior year.

5 May 2010

Ago2 protein helps generate microRNAs: CSHL researchers

MicroRNAs are small bits of RNA within cells that wield enormous power. They influence virtually every biological process by controlling the "expression" of genes. Helping them in exerting this control is a unique class of proteins called Argonautes.

29 Apr 2010

NIDCR awards Selenium $912,943 grant for development of antimicrobial dental devices and water lines

The National Institute of Dental and Craniofacial Research (NIDCR), one of the National Institutes of Health (NIH), has issued a two-year $912,943 grant to biopharmaceutical company Selenium, Ltd. to support the development of antimicrobial dental devices and water lines. In the two-part grant the NIH has approved $492,972 for year one and $419,971 for year two dependent on achieving year one objectives.

29 Apr 2010

Nu Skin Enterprises' revenue for first-quarter 2010 increases 23% to $364.1M

Nu Skin Enterprises, Inc. today announced record first-quarter results, with revenue of $364.1 million, a 23 percent improvement over the prior-year period. Quarterly revenue was positively impacted 8 percent by foreign currency fluctuations.

28 Apr 2010

Avivia Health announces new portal with digital health coaching and interactive tools for employee members

To help employee members take a more proactive role in managing their own health programs, Avivia Health From Kaiser Permanente today announced the introduction of Your Health Center, a new portal based on Web 2.0 technology that provides user members with powerful digital health coaching and interactive tools. Avivia Health is the only national provider of Wellness and Condition Management Solutions based on 60 years of evidence-based practices by its parent organization, Kaiser Permanente.

27 Apr 2010

Catalyst Pharmaceutical Partners regains compliance for continued listing on The Nasdaq Capital Market

Catalyst Pharmaceutical Partners, Inc. announced today that it has received notice from The NASDAQ Stock Market confirming that the Company has regained compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.

27 Apr 2010

IDEXX Laboratories' first-quarter 2010 revenues increase 14% to $268.5M

IDEXX Laboratories, Inc., today reported that revenues for the first quarter of 2010 increased 14% to $268.5 million, from $236.5 million for the first quarter of 2009. Organic revenue growth, as defined below, was 9%. Earnings per diluted share for the quarter ended March 31, 2010 increased 28% to $0.55, compared to $0.43 for the same period in the prior year.

23 Apr 2010

New studies on cancer prevention presented at 101st AACR Annual Meeting 2010

Interest in cancer prevention is increasing as scientists continue to learn new information and confirm what was already suspected.

22 Apr 2010

Genmab introduces new pre-clinical antibody program and novel bispecific antibody technology

Genmab A/S will announce today at its Annual General Meeting a new pre-clinical antibody program, HuMax-cMet,as well as a novel next generation bispecific antibody technology.

22 Apr 2010

Study analyzes effects of untimely and sudden parental death on childhood development

Losing a parent to suicide makes children more likely to die by suicide themselves and increases their risk of developing a range of major psychiatric disorders, according to a study led by Johns Hopkins Children's Center that is believed to be the largest one to date on the subject.

22 Apr 2010

DiscoveryBioMed awarded NIH SBIR Phase 1 grant to discover and develop anti-inflammatory phytochemicals

DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a $200,000 Small Business Innovations Research (SBIR) Phase 1 grant by the National Institutes of Health (NIH) to continue research into the discovery and development of anti-inflammatory phytochemicals to address complications associated with nasal and pulmonary inflammation, dermatitis, and kidney disorders with an inflammatory component.

21 Apr 2010

Study reveals increased risk for cancer among Latino populations

New findings from epidemiology and observational studies show an increased risk for cancer among Latino populations, but unique demographic characteristics suggest the problem may be worse than currently known.

19 Apr 2010

Emdeon achieves compliance with CAQH CORE Phase II rules

Emdeon Inc., a leading provider of healthcare revenue and payment cycle management solutions, today announced it has achieved compliance with the CAQH® Committee on Operating Rules for Information Exchange (CORE) Phase II rules. CAQH, a nonprofit alliance of health plans and trade associations, is a catalyst for industry collaboration on initiatives that simplify healthcare administration for health plans and providers, resulting in a better care experience for patients and caregivers. Emdeon achieved CORE Phase I compliance in March 2007.

16 Apr 2010

Preclinical results of Avila Therapeutics' AVL-181 and AVL-192 presented at EASL Annual Meeting

Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on two of its Hepatitis C Virus protease inhibitors, AVL-181 and AVL-192. These inhibitors, due to their unique mechanism of action with superior selectivity and potency, have potential as best-in-class, pan-genotype HCV therapeutics.

16 Apr 2010

Campaign for Better Care focuses on older adults with multiple health problems

"Will you help her?" That's the question the Campaign for Better Care, led by the National Partnership for Women & Families, Community Catalyst and the National Health Law Program, is asking policymakers today in new print and banner ads running in The Hill, Politico and Roll Call.

15 Apr 2010

Catalyst Pharmaceutical Partners, NIDA to jointly conduct Phase II(b) trial of CPP-109 for cocaine addiction

Catalyst Pharmaceutical Partners, Inc. announced today that it has signed a definitive Clinical Trial Agreement (CTA) with the National Institute on Drug Abuse (NIDA) to jointly conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, for the treatment of cocaine addiction. As part of the CTA, NIDA, under their agreement with Veteran's Administration Cooperative Studies Program, will provide substantial resources for the estimated $10 million trial cost.

15 Apr 2010

Catalyst News and Research

Experts propose policy solutions to help the U.S. prepare for increasing number of geriatric patients

TearScience completes $44.5 million Series C funding

Decisive impact of informatics on nanomedicine

Each year up to 85% of health center patients experience unmet legal needs: Study

Catalyst Health Solutions' first-quarter 2010 net income up 26%

Ago2 protein helps generate microRNAs: CSHL researchers

NIDCR awards Selenium $912,943 grant for development of antimicrobial dental devices and water lines

Nu Skin Enterprises' revenue for first-quarter 2010 increases 23% to $364.1M

Avivia Health announces new portal with digital health coaching and interactive tools for employee members

Catalyst Pharmaceutical Partners regains compliance for continued listing on The Nasdaq Capital Market

IDEXX Laboratories' first-quarter 2010 revenues increase 14% to $268.5M

New studies on cancer prevention presented at 101st AACR Annual Meeting 2010

Genmab introduces new pre-clinical antibody program and novel bispecific antibody technology

Study analyzes effects of untimely and sudden parental death on childhood development

DiscoveryBioMed awarded NIH SBIR Phase 1 grant to discover and develop anti-inflammatory phytochemicals

Study reveals increased risk for cancer among Latino populations

Emdeon achieves compliance with CAQH CORE Phase II rules

Preclinical results of Avila Therapeutics' AVL-181 and AVL-192 presented at EASL Annual Meeting

Campaign for Better Care focuses on older adults with multiple health problems

Catalyst Pharmaceutical Partners, NIDA to jointly conduct Phase II(b) trial of CPP-109 for cocaine addiction

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News